EX-5.2 2 sbfm_ex52.htm OPINION OF ANDREW I. TELSEY, P.C. RE: LEGALITY sbfm_ex52.htm
Exhibit 5.2
 
Andrew I. Telsey, P.C.  Attorney at Law
12835 E. Arapahoe Road, Tower One, Penthouse #803, Englewood, Colorado 80112
Telephone:  303/768-9221 • Facsimile:  303/768-9224 • E-Mail:  andrew@telseylaw.com


January 27, 2014


Board of Directors
Sunshine Biopharma, Inc.
469 Jean-Talon West
3rd Floor
Montreal, Quebec, Canada H3N 1R4

Re:           Sunshine Biopharma, Inc.
 
Information Statement/Form S-4 Registration Statement and related Prospectus

Dear Sirs:

We have acted as counsel to Sunshine Biopharma, Inc. (the "Registrant"), a Colorado corporation, in connection with the preparation of the above-referenced S-4 Registration Statement and related Prospectus ("Registration Statement"), relating to the registration of 60,499,061 shares of common stock, $.001 par value per share to be exchanged by the Registrant’s shareholders as part of the Continuation (as defined in the Prospectus).  We have examined the Articles of Incorporation and By-laws of the Registrant, and such other documents as we have deemed relevant and material.  Based on the foregoing, and certain representations of the officers, directors and representatives of the Registrant as to factual matters, it is the opinion of this office that:

     1.  The Registrant has been duly organized and is validly existing and in good standing in the State of Colorado, the jurisdiction of its incorporation.
 
  2.  The aforementioned securities to be registered pursuant to the Registration Statement have been duly and validly authorized by the requisite corporate action in accordance with the general requirements of corporation law.  The aforesaid securities are validly authorized and issued, fully paid and nonassessable in accordance with the general requirements of Colorado corporation law including the statutory provisions, all applicable provisions of the Colorado Constitution and reported judicial decisions interpreting those laws.

Yours truly,

ANDREW I. TELSEY, P.C.